|
Non-infectious pneumonitis
|
Asymptomatic
|
Symptomatic; not interfering with ADL
|
Severe symptoms; interfering with ADL, oxygen indicated
|
Life-threatening respiratory comprise; urgent intervention indicated
|
|
Infections
|
None
|
Localised; local intervention indicated
|
IV antibiotic, antifungal or antiviral intervention indicated; radiology/operative intervention indicated
|
Life-threatening consequences, e.g. septic shock, hypotension, acidosis, necrosis
|
|
Stomatitis
|
Minimal; normal diet
|
Symptomatic, but can eat and swallow; modified diet
|
Symptomatic; unable to adequately aliment or hydrate orally
|
Symptoms associated with life-threatening consequences
|
|
Rash
|
Macular or popular eruption or erythema without associated symptoms
|
Macular or papular eruption or erythema with pruritus or other associated symptoms; localised desquamation or other lesions covering
|
Severe, generalised erythroderma or macular, papular or vesicular eruption; desquamation covering ≥50% BSA
|
Generalised exfoliative, ulcerative, or bullous dermatitis
|
|
Metabolic events
|
|
Hypercholesterolaemia,
|
>ULN–300
|
>300–400
|
>400–500
|
>500
|
|
mg/dL (mmol/L)
|
(>ULN–7.75)
|
(>7.75–10.34)
|
(>10.34–12.92)
|
(>12.92)
|
|
Hyperglycaemia,
|
>ULN–160
|
>160–250
|
>250–500
|
>500
|
|
mg/dL (mmol/L)
|
(>ULN–8.9)
|
(>8.9–13.9)
|
(>13.9–27.8)
|
(>27.8 or acidosis)
|
|
Hypophosphataemia,
|
<LLN–2.5
|
<2.5–2.0
|
<2.0–1.0
|
<1.0
|
|
mg/dL (mmol/L)
|
(<LLN–0.8)
|
(<0.8–0.6)
|
(<0.6–0.3)
|
(<0.3)
|
|
Hypertriglyceridaemia
|
>ULN–2.5 × ULN
|
>2.5–5.0 × ULN
|
>5.0–10.0 × ULN
|
>10.0 × ULN
|
| |
-
|
-
|
-
|
-
|
|
Hyperiuricaemia, mg/dL (mmol/L)
|
>ULN–10 (≤0.59 without physiologic consequences)
|
-
|
>ULN–10 (≤0.59 without physiologic consequences)
|
>10 (>0.59)
|
|
Myelosuppression, 109/L
|
|
Platelets
|
<LLN–75.0
|
<75.0–50.0
|
<50.0–25.0
|
<25.0
|
|
Neutrophils
|
<LLN–1.5
|
<1.5–1
|
<1.0–0.5
|
<0.5
|
